MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2 trial evaluating MGTA-145 and plerixafor for HSC mobilization (NCT04552743). Plerixafor was given subcutaneously followed 2 h later by MGTA-145 (0.03 mg/kg) intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected <6 ×10⁶ CD34+ cells/kg. Lenalidomide and anti-CD38 antibody were part of induction therapy in 92% (n = 23) and 24% (n = 6) of patients, respectively. Median total HSC cell yield (CD34+ cells/kg × 10⁶) was 5.0 (range: 1.1–16.2) and day 1 yield was 3.4 (range: 0.3–16.2). 88% (n = 22) of patients met the primary endpoint of collecting 2 ×10⁶ CD34+ cells/kg in ≤ two days, 68% (n = 17) in one day. Secondary endpoints of collecting 4 and 6 × 10⁶ CD34+ cells/kg in ≤ two days were met in 68% (n = 17) and 40% (n = 10) patients. Grade 1 or 2 adverse events (AE) were seen in 60% of patients, the most common AE being grade 1 pain, usually self-limited. All 19 patients who underwent transplant with MGTA-145 and plerixafor mobilized HSCs engrafted successfully, with durable engraftment at day 100. 74% (17 of 23) of grafts with this regimen were minimal residual disease negative by next generation flow cytometry. Graft composition for HSCs and immune cells were similar to a contemporaneous cohort mobilized with G-CSF and plerixafor.

MGTA-145 或 GROβT 是一种 CXCR2 激动剂，在临床前研究和健康志愿者中，普乐沙福在造血干细胞 （HSC） 动员方面显示出有希望的活性。25 名多发性骨髓瘤患者参加了一项评估 MGTA-145 和普乐沙福用于 HSC 动员的 2 期试验 （NCT04552743）。皮下注射普乐沙福，2 小时后静脉注射 MGTA-145 （0.03 mg/kg），当天单采术。在收集 <6 ×10⁶ CD34 + 细胞/kg 的患者中，可以重复动员/单采术第二天。来那度胺和抗 CD38 抗体分别是 92% （n = 23） 和 24% （n = 6） 患者诱导治疗的一部分。HSC 细胞总产量中位数（CD34+ 细胞/kg × 10⁶）为 5.0（范围：1.1-16.2），第 1 天产量为 3.4（范围：0.3-16.2）。88% （n = 22） 的患者达到了主要终点，即在 ≤ 天内收集 2 ×10⁶ 个 CD34+ 细胞/kg，68% （n = 17） 在一天内收集。68% （n = 17） 和 40% （n = 10） 患者达到 ≤ 2 天内收集 4 和 6 ×^{10 个} CD34 + 细胞/kg 的次要终点。60% 的患者出现 1 级或 2 级不良事件 （AE），最常见的 AE 是 1 级疼痛，通常是自限性的。所有 19 例接受 MGTA-145 和 plerixafor 动员 HSC 移植的患者均成功植入，第 100 天进行持久植入。采用该方案的移植物中有 74% （23 例中的 17 例） 通过下一代流式细胞术检测为微小残留病灶阴性。HSCs 和免疫细胞的移植物组成与用 G-CSF 和 plerixafor 动员的同期队列相似。